EP
BHVN

Eversept Partners’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Eversept Partners’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-637,139
Closed -$96.3M – 85
2022
Q3 		$96.3M Buy
637,139
+4,345
+0.7% +$644K 8.35% 2
2022
Q2 		$92.2M Sell
632,794
-11,872
-2% -$1.52M 6.56% 2
2022
Q1 		$76.4M Buy
644,666
+329,537
+105% +$41.1M 5.87% 2
2021
Q4 		$43.4M Buy
+315,129
New +$40.1M 2.77% 10
2021
Q2 		– Sell
-242,172
Closed -$16.6M – 116
2021
Q1 		$16.6M Buy
242,172
+138,408
+133% +$11.2M 0.86% 28
2020
Q4 		$8.89M Sell
103,764
-217,817
-68% -$18.5M 1.04% 26
2020
Q3 		$20.9M Sell
321,581
-126,683
-28% -$8.3M 4.65% 8
2020
Q2 		$32.8M Buy
448,264
+341,879
+321% +$18.2M 4.49% 5
2020
Q1 		$3.62M Buy
+106,385
New +$4.86M 0.9% 26

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Eversept Partners's BHVN Position: Q4 2022 in Review

Eversept Partners sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 637,139 shares — an estimated $96.3M sold.

Eversept Partners first reported a position in BHVN in Q1 2020 and held it in 9 quarters. The position peaked at $96.3M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Eversept Partners reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Eversept Partners sold 637,139 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $96.3M.
  • Eversept Partners first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2020 and held it in 9 quarters.
  • Eversept Partners's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $96.3M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Eversept Partners's 13F filing for Q4 2022, filed 14 Feb 2023.